Janet P. Baxter

Janet P. Baxter

Auto-generated profile, based on publicly available information

Janet P. Baxter

Ninewells Hospital and Medical School, Dundee, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Clinical Nutrition
Verified
Journal Article
Open access
LPLoris Pironi
Loris Pironi
JAJann Arends
Jann Arends
JBJanet Baxter
Janet Baxter
FBFederico Bozzetti
Federico Bozzetti
RPRosa Burgos Peláez
Rosa Burgos Peláez
JSJon Shaffer
Jon Shaffer
Intestinal failure (IF) is not included in the list of PubMed Mesh terms, as failure is the term describing a state of non functioning of other organs, and as such is not well recognized. No scientific society has yet devised a formal definition and classification of IF. The European Society for Clinical Nutrition and Metabolism guideline committee endorsed its "home artificial nutrition and chronic IF" and "acute IF" special interest groups to write recommendations on these issues. After a Medline Search, in December 2013, for "intestinal failure" and "review"[Publication Type], the project was developed using the Delphi round methodology. The final consensus was reached on March 2014, after 5 Delphi rounds and two live meetings. The recommendations comprise the definition of IF, a functional and a pathophysiological classification for both acute and chronic IF and a clinical classification of chronic IF. IF was defined as "the reduction of gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation is required to maintain health and/or growth". This formal definition and classification of IF, will facilitate communication and cooperation among professionals in clinical practice, organization and management, and research.

1 August 2009 in Clinical Nutrition
Verified
Journal Article
Closed access
MSMichael Staun
Michael Staun
LPLoris Pironi
Loris Pironi
FBFederico Bozzetti
Federico Bozzetti
JBJanet Baxter
Janet Baxter
AFAlastair Forbes
Alastair Forbes
AGAndré Van Gossum
André Van Gossum

10 November 2010 in Gut
Verified
Journal Article
Closed access
PDF file
LPLoris Pironi
Loris Pironi
FJFrancisca Joly
Francisca Joly
AFAlastair Forbes
Alastair Forbes
VCVirginie Colomb
Virginie Colomb
MLMalgorzata Lyszkowska
Malgorzata Lyszkowska
H(Home Artificial Nutrition & Chronic Intestinal Failure Working Group of the European Society for Clinical Nutrition and Metabolism (ESPEN)
Home Artificial Nutrition & Chronic Intestinal Failure Working Group of the European Society for Clinical Nutrition and Metabolism (ESPEN)
Background The indications for intestinal transplantation (ITx) are still debated. Knowing survival rates and causes of death on home parenteral nutrition (HPN) will improve decisions. Methods A prospective 5-year study compared 389 non-candidates (no indication, no contraindication) and 156 candidates (indication, no contraindication) for ITx. Indications were: HPN failure (liver failure; multiple episodes of catheter-related venous thrombosis or sepsis; severe dehydration), high-risk underlying disease (intra-abdominal desmoids; congenital mucosal disorders; ultra-short bowel), high morbidity intestinal failure. Causes of death were defined as: HPN-related, underlying disease, or other cause. Results The survival rate was 87% in non-candidates, 73% in candidates with HPN failure, 84% in those with high-risk underlying disease, 100% in those with high morbidity intestinal failure and 54%, in ITx recipients (one non-candidate and 21 candidates) (p2 years (p=0.006). In candidates, the death HRs were increased in those with desmoids (7.1; 95% CI 2.5 to 20.5; p=0.003) or liver failure (3.4; 95% CI 1.6 to 7.3; p=0.002) compared to non-candidates. In deceased candidates, the indications for ITx were the causes of death in 92% of those with desmoids or liver failure, and in 38% of those with other indications (p=0.041). In candidates with catheter-related complications or ultra-short bowel, the survival rate was 83% in those who remained on HPN and 78% after ITx (p=0.767). Conclusions HPN is confirmed as the primary treatment for intestinal failure. Desmoids and HPN-related liver failure constitute indications for life-saving ITx. Catheter-related complications and ultra-short bowel might be indications for pre-emptive/rehabilitative ITx. In the early years after commencing HPN a life-saving ITx could be required for some patients at higher risk of death from their underlying disease.

1 August 2006 in Clinical Nutrition
Verified
Journal Article
Closed access
JBJanet P. Baxter
Janet P. Baxter
PFPeter M. Fayers
Peter M. Fayers
AMAlastair W. McKinlay
Alastair W. McKinlay

1 July 2008 in Gastroenterology
Verified
Journal Article
Closed access
LPLoris Pironi
Loris Pironi
AFAlastair Forbes
Alastair Forbes
FJFrancisca Joly
Francisca Joly
VCVirginie Colomb
Virginie Colomb
MLMalgorzata Lyszkowska
Malgorzata Lyszkowska
MSMichael Staun
Michael Staun

1 August 2018 in Clinical Nutrition
Verified
Journal Article
Closed access
FJFrancisca Joly
Francisca Joly
JBJanet Baxter
Janet Baxter
MSMichael Staun
Michael Staun
DKDarlene G. Kelly
Darlene G. Kelly
YHYi Lisa Hwa
Yi Lisa Hwa
LPLoris Pironi
Loris Pironi